US e-cigarette company Kaival Group recently released a report stating that its revenue for the third quarter of the 2022 fiscal year was $3.8 million, up from $3.2 million for the same period last year. Its gross profit was $442,100, compared to a loss of $84,300 for the same period last year.
Kaval Group attributes a portion of its increased revenue to a court ruling in August that put on hold the Food and Drug Administration's (FDA) marketing denial order for the company's non-tobacco flavored Bidi Stick e-cigarette. The US appeals court found that the FDA did not adequately consider Kaval's marketing and access restrictions plan and ordered further review of the company's pre-market tobacco product application while allowing it to continue selling its product.
Eric Mose, President and Chief Operating Officer of Kewal Group, has announced that the company is partnering with Fimo International to sell their products in global markets.
The content of this article is excerpted or reprinted from third-party sources with ownership of copyrights belonging to the original media and authors. If there is any infringement, please contact us for deletion. Any units or individuals wishing to reprint must contact the author and refrain from direct reprinting.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
